ELI LILLY AND COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 769.8 USD | +0.41% |
|
-1.92% | +31.42% |
| 02:12pm | FOMO is Back |  |
| May. 06 | People with two copies of a risk gene have genetic form of Alzheimer's, scientists say | RE |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 42.81B | Sales 2025 * | 52.14B | Capitalization | 690B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.94B | Net income 2025 * | 16.29B | EV / Sales 2024 * | 16.6 x |
| Net Debt 2024 * | 19.98B | Net Debt 2025 * | 15.29B | EV / Sales 2025 * | 13.5 x |
| P/E ratio 2024 * |
57.1
x | P/E ratio 2025 * |
41.8
x | Employees | 43,000 |
| Yield 2024 * |
0.68% | Yield 2025 * |
0.78% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
| 1 day | +0.28% | ||
| 1 week | -1.92% | ||
| Current month | -1.92% | ||
| 1 month | -1.44% | ||
| 3 months | +5.61% | ||
| 6 months | +27.70% | ||
| Current year | +31.42% |
1 week
730.34
782.61
1 month
718.30795.50
Current year
579.05800.78
1 year
419.80800.78
3 years
191.75800.78
5 years
101.36800.78
10 years
57.81800.78
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 00-12-31 |
Ruth Gimeno
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.49% | 18 M€ | +5.44% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 764 | -0.34% | 255 111 |
| 24-05-06 | 766.7 | +4.31% | 3,398,280 |
| 24-05-03 | 735 | -2.77% | 4,595,138 |
| 24-05-02 | 755.9 | -2.68% | 3,205,628 |
| 24-05-01 | 776.8 | -0.56% | 2,804,838 |
Delayed Quote Nyse, May 07, 2024 at 09:42 am EDT
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
766.7
USD
Average target price
848.3
USD
Spread / Average Target
+10.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.42% | 690B | |
| +26.01% | 546B | |
| -4.77% | 358B | |
| +17.69% | 323B | |
| +5.34% | 287B | |
| +14.64% | 235B | |
| +5.60% | 199B | |
| -9.73% | 195B | |
| +4.67% | 161B | |
| -1.30% | 159B |
- Stock Market
- Equities
- LLY Stock